Phaseline

Companies › Aelis Farma

Aelis Farma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AEF0217
GABA-positive allosteric modulator (GABAergic steroid)
GABAPhase 2Down Syndrome (Trisomy 21)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07334912AEF0217Phase 2Down Syndrome (Trisomy 21)OtherDec 2027

Targets

GABA (1)

Companies with the same targets

PleoPharma Neurona Therapeutics

Companies built like this

Angitia Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.